Fusion Research
Research analyst, oil & gas, tech, mid-cap

Charles River Laboratories: Why Bulls Should Be Worried

Charles River Laboratories (NYSE:CRL) is facing headwind issues in its research and model services, or RMS segment, which contributes approximately 61% of the total net sales of the company and posted $182.5 million revenue in the first quarter of 2013. The total revenue declined by 2.1% compared to the previous year, but it grew by about 6% compared to its previous quarter. Most of its biopharmaceutical clients set their budgets and spending priorities for the coming year in the last quarter of the year. And hence, the last quarters never generate higher revenue. As a result, the quarterly growth, even though it is impressive, doesn't look promising to me.

Charles River acquired Accugenix and Vital River under its...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details